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 A Public Health Action Plan to Combat Antimicrobial Resistance  
 Executive Summary 
 
This Public Health Action Plan to Combat Antimicrobial Resistance (Action Plan) was developed 
by an interagency Task Force on Antimicrobial Resistance that was created in 1999.  The Task Force 
is co-chaired by the Centers for Disease Control and Prevention, the Food and Drug Administration, 
and the National Institutes of Health and also includes the Agency for Healthcare Research and Quality, 
the Health Care Financing Administration, the Health Resources and Services Administration, the 
Department of Agriculture, the Department of Defense, the Department of Veterans Affairs, and the 
Environmental Protection Agency. 
 
The Action Plan reflects a broad-based consensus of federal agencies on actions needed to address 
antimicrobiala resistance (AR).  Input from state and local health agencies, universities, professional 
societies, pharmaceutical companies, health care delivery organizations, agricultural producers, 
consumer groups, and other members of the public was important in developing the plan.  While some 
actions are already underway, complete implementation of this plan will require close collaboration with 
all of these partners,b a major objective of the process.  The plan will be implemented incrementally, 
dependent on the availability of resources. 
 
The Action Plan provides a blueprint for specific, coordinated federal actions to address the emerging 
threat of antimicrobial resistance.  This document is Part I of the Action Plan, focusing on domestic 
issues.  Since AR transcends national borders and requires a global approach to its prevention and 
control, Part II of the plan, to be developed subsequently, will identify actions that more specifically 
address international issues.  The Action Plan, Part I (Domestic Issues), includes four focus areas: 
Surveillance, Prevention and Control, Research, and Product Development.  A summary of the top 
priority goals and action items in each focus area follows.   
 
Surveillance 
 
Unless AR problems are detected as they emerge – and actions are taken quickly to contain them – the 
                                                                 
aIn this document, the term “antimicrobial” is used inclusively to refer to any agent (including an 
antibiotic) used to kill or inhibit the growth of microorganisms (bacteria, viruses, fungi, or parasites.) This 
term applies whether the agent is intended for human, veterinary or agricultural applications. 
bImplementation of this Action Plan requires working with a wide variety of partners, e.g. state and 
local health agencies, universities, professional societies, pharmaceutical and biotechnology companies, 
health care delivery organizations, insurers, agricultural producers, consumer groups, and the public. A 
wide variety of expertise is needed, e.g., from clinicians, consumers, pharmacists, microbiologists, 
epidemiologists, behavioral and social scientists, economists, health policy researchers, and others.  
Partners and expertise needed will vary with different action items. 
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world may soon be faced with previously treatable diseases that have again become untreatable, as in 
the pre-antibiotic era.  Priority Goals and Action Items in this focus area address ways to: 
 
· Develop and implement a coordinated national plan for AR surveillance; 
· Ensure the availability of reliable drug susceptibility data for surveillance; 
· Monitor patterns of antimicrobial drug use; and 
· Monitor AR in agricultural settings to protect the public’s health by ensuring a safe food supply as 
well as animal and plant health. 
 
A coordinated national surveillance plan for monitoring AR in microorganisms that pose a threat to 
public health will be developed and implemented.  The plan will specify activities to be conducted at 
national, state, and local levels; define the roles of participants; promote the use of standardized 
methods; and provide for timely dissemination of data to interested parties, e.g., public health officials, 
clinicians, and researchers.  Needed core capacities at state and local levels will be defined and 
supported.   When possible, the plan will coordinate, integrate, and build on existing disease surveillance 
infrastructure.  All surveillance activities will be conducted with respect for patient and institutional 
confidentiality. 
 
The availability of reliable drug susceptibility data is essential for AR surveillance.  The accuracy 
of AR detection and reporting will be improved through training and proficiency testing programs for 
diagnostic laboratories and by promoting and further refining standardized methods for detecting drug 
resistance in important pathogens, including bacteria, parasites, fungi, and viruses.  Public and private 
sector partners will address barriers to AR testing and reporting, e.g., barriers due to changes in health 
care delivery. 
 
A plan to monitor patterns of antimicrobial drug use will be developed and implemented as an 
important component of the national AR surveillance plan.  This information is essential to interpret 
trends and variations in rates of AR, improve our understanding of the relationship between drug use 
and resistance, identify and anticipate gaps in availability of existing drugs, and identify interventions to 
prevent and control AR. 
 
Improved surveillance for AR in agricultural settings will allow early detection of resistance trends 
in pathogens that pose a risk to animal and plant health, as well as in bacteria that enter the food supply. 
 Agricultural surveillance data will also help improve understanding of the relationship between 
antimicrobial drug and pesticide use and the emergence of drug resistance. 
 
Prevention and Control 
 
The prevention and control of drug-resistant infections requires measures to promote the appropriate 
usec of antimicrobial drugs and prevent the transmission of infections (whether drug-resistant or not).  
                                                                 
cIn this Action Plan, appropriate antimicrobial drug use is defined as use that maximizes therapeutic 
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Priority Goals and Action Items in this focus area address ways to: 
 
· Extend the useful life of antimicrobial drugs through appropriate use policies that discourage overuse 
and misuse; 
· Improve diagnostic testing practices; 
· Prevent infection transmission through improved infection control methods and use of vaccines; 
· Prevent and control emerging AR problems in agriculture, human and veterinary medicine; and 
· Ensure that comprehensive programs to prevent and control AR involve a wide variety of 
nonfederal partners and the public so these programs become a part of routine practice nationwide. 
 
Appropriate drug-use policies will be implemented through a public health education campaign on 
appropriate antimicrobial drug use as a national health priority.  Other actions in support of appropriate 
drug use will include reducing inappropriate prescribing through development of clinical guidelines and 
computer-assisted decision support, considering regulatory changes, supporting other interventions 
promoting education and behavior change among clinicians, and informing consumers about the uses 
and limitations of antimicrobial drugs. 
 
Improved diagnostic practices will be promoted by encouraging the use of rapid diagnostic methods 
to guide drug prescribing, facilitating direct consultation between clinicians and laboratory personnel with 
appropriate expertise and authority, and promoting the use of appropriate laboratory testing methods.  
Guidelines, training, and regulatory and reimbursement policies will be utilized to promote improved 
diagnostic practices. 
 
Reduced rates of infection transmission will be addressed through public health campaigns that 
promote vaccination and hygienic practices such as hand washing, safe food handling, and other 
behaviors associated with prevention of infection transmission.  Infection control in health care settings 
will be enhanced by developing new interventions based on rapid diagnosis, improved understanding of 
the factors that promote cross-infection, and modified medical devices or procedures that reduce the 
risk of infection. 
 
The prevention and control of AR in agriculture  and veterinary medicine requires 1) improved 
understanding of the risks and benefits of antimicrobial use and ways to prevent the emergence and 
spread of resistance; 2) development and implementation of principles for appropriate antimicrobial 
drug use in the production of food animals and plants; 3) improved animal husbandry and food-
production practices to reduce the spread of infection; and 4) a regulatory framework to address the 
need for antimicrobial drug use in agriculture and veterinary medicine while ensuring that such use does 
not pose a risk to human health. 
                                                                                                                                                                                                                 
impact while minimizing toxicity and the development of resistance.  In practice, this means prescribing 
antimicrobial therapy when and only when beneficial to a patient; targeting therapy to the desired 
pathogens; and using the appropriate drug, dose, and duration. 
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Comprehensive, multifaceted programs  involving a wide variety of nonfederal partners and the 
public are required to prevent and control AR.  The AR Task Force agencies will ensure ongoing input 
from, review by, and collaboration with nonfederal partners.  The appropriate agencies will support 
demonstration projects that use multiple interventions to prevent and control AR (e.g., through 
surveillance, appropriate drug use, optimized diagnostic testing, immunization practice, and infection 
control).  The Task Force agencies will encourage the incorporation of effective programs into routine 
practice by implementing model programs in federal health care systems and promoting the inclusion of 
AR prevention and control activities as part of quality assurance and accreditation standards for health 
care delivery nationwide. 
 
Research 
 
Understanding the fundamental processes involved in antimicrobial resistance within microbes and the 
resulting impact on humans, animals, and the environment forms an important basis for influencing and 
changing these processes and outcomes.  Basic and clinical research provides the fundamental 
knowledge necessary to develop appropriate responses to antimicrobial resistance emerging and 
spreading in hospitals, communities, farms, and the food supply.  Priority Goals and Action Items in this 
focus area address ways to: 
 
· Increase understanding of microbial physiology, ecology, genetics and mechanisms of resistance; 
· Augment the existing research infrastructure to support a critical mass of researchers in AR and 
related fields; and 
· Translate research findings into clinically useful products, such as novel approaches to detecting, 
preventing, and treating antimicrobial resistant infections. 
 
Needs in the field of AR research will be identified and addressed through a government-wide 
program review with external input.  Additional research is needed, for example, on the epidemiology of 
resistance genes; on mechanisms of AR emergence, acquisition, spread, and persistence; and on the 
effects of antibiotics used as agricultural growth promotants on microbes that live in animals, humans, 
plants, soil and water.  Further study is also required to determine whether variations in drug use 
regimens may stimulate or reduce AR emergence and spread.  Improved understanding of the causes of 
AR emergence will lead to the development of tools for reducing microbial resistance, as well as for 
predicting where AR problems are likely to arise. 
 
A comprehensive research infrastructure  will help ensure a critical mass of AR researchers who will 
interact, exchange information, and stimulate new discoveries.  This aim will be achieved through the 
appropriate strategies and scientific conferences that promote research on AR.  The AR Task Force 
agencies will work with the academic and industrial research communities to attract AR researchers, 
prioritize needs, identify key opportunities, and optimize the utilization of resources to address AR 
problems. 
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The translation of research findings into innovative clinical products to treat, prevent, or 
diagnose drug-resistant infections is an area in which the federal government can play an important role, 
focusing on gaps not filled by the pharmaceutical industry or by other nongovernment groups.  Special 
efforts will be placed on the identification, development and testing of rapid, inexpensive, point-of-care 
diagnostic methods to facilitate appropriate use of antimicrobials.  The AR Task Force agencies will 
also encourage basic research and clinical testing of diagnostic methods, novel treatment approaches, 
new vaccines, and other prevention approaches for resistant infections. 
 
Product Development  
 
As antimicrobial drugs lose their effectiveness, new products must be developed to prevent, rapidly 
diagnose, and treat infections.  The Priority Goals and Action Items in this focus area address ways to: 
 
· Ensure that researchers and drug manufacturers are informed of current and projected gaps in the 
arsenal of antimicrobial drugs, vaccines, and diagnostics and of potential markets for these products 
(designated here as “AR products”); 
· Stimulate the development of priority AR products for which market incentives are inadequate, 
while fostering their appropriate use; and 
· Optimize the development and use of veterinary drugs and related agricultural products that reduce 
the transfer of resistance to pathogens that can infect humans. 
 
Current and projected gaps in the arsenal of AR products and potential markets for these 
products will be reported to researchers and drug manufacturers through an interagency working group 
convened to identify and publicize priority public health needs. 
 
The development of urgently needed AR products will be stimulated throughout the process from 
drug discovery through licensing.  The regulatory process for AR products will continue to be 
streamlined, and incentives that promote the production and appropriate use of priority AR products 
can be evaluated in pilot programs that monitor costs and assess the return on the public investment. 
 
The production of veterinary AR products that reduce the risk of development and transfer of 
resistance to drugs used in human clinical medicine will be expedited through a streamlined regulatory 
and approval process.  As with drugs for the treatment of human infections, pilot programs can be 
initiated to evaluate incentives that encourage the development and appropriate use of priority products 
that meet critical animal and plant health needs. 
 
Private and public partners will also evaluate ways to improve or reduce the agricultural use of particular 
antimicrobial drugs, as well as ways to prevent infection, such as the use of veterinary vaccines, changes 
in animal husbandry, and the use of competitive exclusion products (i.e., treatments that affect the 
intestinal flora of food animals). 
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Top Priority Action Items to Combat Antimicrobial Resistance 
(All 13 items have top priority, regardless of their order in the list) 
 
Surveillance 
· With partners, design and implement a national AR surveillance plan that defines national, regional, 
state, and local surveillance activities and the roles of clinical, reference, public health, and veterinary 
laboratories. The plan should be consistent with local and national surveillance methodology and 
infrastructure that currently exist or are being developed. 
(Action Item #2) 
 
· Develop and implement procedures for monitoring patterns of antimicrobial drug use in human 
medicine, agriculture, veterinary medicine, and consumer products. 
(Action Item #5) 
 
Prevention and Control 
· Conduct a public health education campaign to promote appropriate antimicrobial use as a national 
health priority.  
(Action Item #25) 
 
· In collaboration with many partners, develop and facilitate the implementation of educational and 
behavioral interventions that will assist clinicians in appropriate antimicrobial prescribing.  
(Action Item #26) 
 
· Evaluate the effectiveness (including cost-effectiveness) of current and novel infection-control 
practices for health care and extended care settings and in the community. Promote adherence to 
practices proven to be effective.  
(Action Item #39) 
 
· In consultation with stakeholders, refine and implement the proposed FDA framework for 
approving new antimicrobial drugs for use in food-animal production and, when appropriate, for re-
evaluating currently approved veterinary antimicrobial drugs. 
(Action Item #58) 
 
· Support demonstration projects to evaluate comprehensive strategies that use multiple interventions 
to promote appropriate drug use and reduce infection rates, in order to assess how interventions 
found effective in research studies can be applied routinely and most cost-effectively on a large 
scale. 
(Action Item #63) 
 
Research 
· Provide the research community genomics and other powerful technologies to identify targets in 
critical areas for the development of new rapid diagnostics methodologies, novel therapeutics, 
  
 
 8
and interventions to prevent the emergence and spread of resistant pathogens.   
(Action Item #70) 
 
· In consultation with academia and the private sector, identify and conduct human clinical studies 
addressing AR issues of public health significance that are unlikely to be studied in the private 
sector (e.g., novel therapies, new treatment regimens, and other products and practices).   
(Action Item #75) 
 
· Identify, develop, test, and evaluate new rapid diagnostic methods for human and veterinary 
uses with partners, including academia and the private sector.  Such methods should be 
accurate, affordable, and easily implemented in routine clinical settings (e.g., tests for resistance 
genes, point-of-care diagnostics for patients with respiratory infections and syndromes, and 
diagnostics for drug resistance in microbial pathogens, including in nonculture specimens). 
(Action Item #76) 
 
· Encourage basic and clinical research in support of the development and appropriate use of 
vaccines in human and veterinary medicine in partnership with academia and the private sector. 
(Action Item #77) 
 
Product Development 
· Create an Interagency AR Product Development Working Group to identify and publicize 
priority public health needs in human and animal medicine for new AR products (e.g., innovative 
drugs, targeted spectrum antibiotics, point-of-care diagnostics, vaccines and other biologics, 
anti-infective medical devices, and disinfectants). 
(Action Item #79) 
 
· Identify ways (e.g. financial and/or other incentives or investments) to promote the development 
and/or appropriate use of priority AR products, such as novel compounds and approaches, for 
human and veterinary medicine for which market incentives are inadequate. 
(Action Item #80)  
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Introduction and Overview 
 
Background 
 
In the 1940s, the widespread availability of penicillin and the subsequent discovery of streptomycin led 
to a dramatic reduction in illness and death from infectious diseases.  However, bacteria and other 
disease-causing organisms – viruses, fungi, and parasites – have a remarkable ability to mutate and 
acquire resistance genes from other organisms and thereby develop resistance to antimicrobial drugs.  
When an antimicrobial drug is used, the selective pressure exerted by the drug favors the growth of 
organisms that are resistant to the drug’s action.  The extensive use of antimicrobial drugs has resulted in 
drug resistance that threatens to reverse the miracles of the last half century. 
 
Drug-resistant pathogens are a growing menace to all people, regardless of age, gender, or 
socioeconomic background.  They endanger people in affluent, industrial societies like the United 
States, as well as in less developed nations.  Examples of clinically important microbes that are rapidly 
developing resistance to available antimicrobials include bacteria that cause pneumonia, ear infections, 
and meningitis (e.g., Streptococcus pneumoniae1), skin, bone, lung, and bloodstream infections (e.g., 
Staphylococcus aureus2,3), urinary tract infections (e.g., Escherichia coli4), foodborne infections (e.g., 
Salmonella5), and infections transmitted in health care settings (e.g., enterococci6 and Klebsiella spp.7). 
 
For example, up to 30 percent of S. pneumoniae found in some areas of the United States are no 
longer susceptible to penicillin, and multidrug resistance is common.  Approximately 11 percent of S. 
pneumoniae are resistant to “third generation” cephalosporin antibiotics, and resistance to the newest 
fluoroquinolone antimicrobials has already been reported.8  Nearly all strains of Staphylococcus aureus 
in the United States are resistant to penicillin, and many are resistant to newer methicillin-related drugs.2 
 Since 1997, strains of S. aureus with decreased susceptibility to vancomycin, for many years the only 
uniformly effective treatment, have been reported.9,10 
 
Many other pathogens – including the bacteria that cause tuberculosis11 and gonorrhea,12 human 
immunodeficiency virus,13 the fungi that cause yeast infections,14 and the parasites that cause malaria15 – 
are also becoming resistant to standard therapies.  If we do not act to address the problem of AR, we 
may lose quick and reliable treatment of infections that have been a manageable problem in the United 
States since the 1940s.  Drug choices for the treatment of common infections will become increasingly 
limited and expensive – and, in some cases, nonexistent. 
 
Risk 
While anyone may acquire a drug-resistant infection, certain people are at increased risk, e.g., patients 
in hospitals and children in daycare centers.  Drug-resistant infections may be acquired in health care 
settings (e.g., staphylococcal infections in intensive care units), in the community (e.g. pneumococci 
acquired from a classmate) and through the food supply (e.g., salmonella acquired from meat or eggs), 
both domestically and overseas.  However, resistant microbes are increasingly appearing in new 
settings.  Methicillin-resistant S. aureus, which for 30 years with few exceptions was a problem only in 
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hospitals, is now occurring in the community.3,16 
 
Costs 
The costs of treating AR infections place a significant burden on society – a burden that is likely to grow 
larger as the number of cases of drug-resistant illness increase.  Individuals infected with drug resistant 
organisms are more likely to require hospitalization, to remain in the hospital for a longer time, and to 
have a poor prognosis.  For example, it has been estimated that the in-hospital cost of hospital-acquired 
infections caused by just six common kinds of resistant bacteria are at least $1.3 billion per year, in 
1992 dollars.17 This estimate does not include the costs of infections caused by other pathogens, the 
costs of lost workdays, post-hospital care, or resistant infections in the outpatient or extended care 
facility settings. 
 
Solutions 
AR will always be with us.  The challenge before us is to transform this increasingly urgent threat into a 
manageable problem.  Over the past ten years, the Institute of Medicine,18 the American Society for 
Microbiology,19 World Health Organization20 other panels of distinguished experts, the Congressional 
Office of Technology Assessment,17 and the General Accounting Office 21, 22 have provided 
recommendations and options for government action to address the dangers posed by AR.  The experts 
agree that we need to improve surveillance for emerging AR problems, to prolong the useful life of 
antimicrobial drugs, to develop new drugs, and to utilize other measures, e.g., improved vaccines, 
diagnostics, and infection control measures to prevent and control AR. 
 
Despite the urgency of the problem, the achievement of these goals has not been simple or 
straightforward, and accomplishments to date have been insufficient.  Monitoring, preventing, and 
controlling AR requires sustained effort, commitment, and collaboration among many groups in the 
public and private sectors, and involvement of the general public.  It also requires support and 
leadership from the federal government and a willingness to address complex and sometimes 
controversial scientific, medical, and economic issues. 
 
A Public Health Action Plan to Combat Antimicrobial Resistance 
 
A Public Health Action Plan to Combat Antimicrobial Resistance provides a blueprint for specific, 
coordinated federal government actions to address this emerging threat.  The plan builds upon reports 
prepared by expert panels in recent years.  This document is Part I of the plan, focusing on domestic 
issues.  However, AR transcends national borders and requires a global approach to its prevention and 
control.  Part II of the plan, to be developed after the World Health Organization finalizes its Global 
Strategy for the Containment of Antimicrobial Resistance,23 will identify federal actions that more 
specifically address international issues with input from and in collaboration with WHO and additional 
partners.  A National Action Plan to Combat Multi-drug Resistant Tuberculosis has been published 
previously.24  
 
Plan Development 
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This plan was developed by an Interagency Task Force on Antimicrobial Resistance that was created in 
1999.  The Task Force is co-chaired by the Centers for Disease Control and Prevention (CDC), the 
Food and Drug Administration (FDA), and the National Institutes of Health (NIH), and also includes 
the Agency for Healthcare Research and Quality (AHRQ), the Health Care Financing Administration 
(HCFA), the Health Resources and Services Administration (HRSA), the Department of Agriculture 
(USDA), the Department of Defense (DoD), the Department of Veterans Affairs (DVA), and the 
Environmental Protection Agency (EPA). 
 
The plan is based in part on input obtained at a public meeting held in Atlanta, Georgia, in July 1999.25  
Present at the public meeting were consultants from a wide variety of groups, including state and local 
health agencies, universities, professional societies, pharmaceutical and biotechnology companies, health 
care delivery organizations, agricultural producers, consumer groups, and the public. A draft of the plan 
was released for public comment in June 2000, 26 and the plan was modified following consideration of 
comments received.  
 
Partnerships, Implementation, and Coordination 
The plan reflects a broadly-based consensus of federal agencies on federal actions to combat AR.  
However, implementation of this plan will require collaboration with many partners.b  More specific 
details of these collaborations will be developed by the agencies as the actions are implemented. 
 
The plan will be implemented incrementally as resources become available.  The agencies recognize that 
a number of the items may require either new statutory authority or changes in regulatory requirements.  
The extent to which such measures may be needed to implement a given action item will be considered 
by the agencies involved. 
 
The plan includes a summary and a list of issues, goals, and action items addressing surveillance, 
prevention and control, research, and product development.d  For each action item, coordinator and 
collaborator agencies/departments are specified.  Contingent on available resources, the coordinators 
will assume the primary responsibility of carrying out the specified action items and the collaborators will 
assist and/or carry out part of the specified action.  Additional agencies may become collaborators in 
the future.   
  
The Task Force identified 13 top priority action items.  Approximate timelines were also identified for 
all action items; these timelines provide another indication of priority but also take into account 
prerequisites for certain items and the achievable pace of action on sometimes complex issues.  
Designation of top priorities and timelines was a difficult task given the realization that many items could 
be considered top priority and should ideally begin immediately.  For action items with multiple 
                                                                 
dExcept where specified, these issues, goals, and action items apply to human AR issues and not to 
nonhuman (e.g., agricultural) issues.  Agricultural issues refer to the production of animals and plants, as 
well as fish and other species (aquaculture). 
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component parts, the agencies involved will further develop priorities and timelines, with appropriate 
input from outside partners, as they implement the action item. 
 
The Interagency Task Force will continue to facilitate coordination among agencies and monitor 
implementation of the plan.  During the coming years, the Task Force will publish periodic reports 
detailing how the plan is being implemented, solicit comments from the public, – and if necessary, 
update the plan.  Details of current agency activities regarding AR are beyond the scope of this 
document, but may be obtained by contacting the specific agencies.   
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The Focus Areas 
I. Surveillance 
 
Surveillance of AR is critical to providing early warning of emerging problems, monitoring changing 
patterns of resistance, and targeting and evaluating prevention and control measures.e  Timely 
surveillance information is also necessary for assisting researchers in developing new drugs and for 
providing good patient care.  For example, clinicians should be informed of drug resistance problems in 
their communities that may influence their prescribing decisions in order to help them avoid treatment 
failures.  In addition, monitoring patterns of antimicrobial drug use is needed to interpret trends and 
variations in rates of AR, improve understanding of the relationship between drug use and resistance, 
identify and anticipate gaps in availability of existing drugs, and help identify preventive interventions. 
 
At present, the United States lacks a coordinated national plan for AR surveillance.  Creating a national 
plan requires collaboration with partners in the public and private sectors.  Improved AR surveillance 
depends on enhancing epidemiologic and laboratory capabilities at local, state, and national levels; using 
standardized and reliable laboratory testing methods; and enhancing use of informatics. 
 
A.  Issue:  The United States lacks a coordinated national plan for surveillance of: 
· AR emergence in organism-drug combinations of public health importance and 
· Antimicrobial drug use in human and nonhuman settings. 
 
1.  Goal: Collaborate with appropriate partners to develop procedures and methods for  
surveillance of AR emergence in organism-drug combinations of public health 
importance. 
 
a. Action Items 
                         
(1)Determine which organisms and susceptibility to specific antimicrobial drugs should be 
under surveillance and create a mechanism for periodic updating of this list. 
Coordinators: CDC, FDA, USDA, EPA 
Timeline: Initiated 
  
 
(2) TOP PRIORITY ACTION ITEM  - With partners, design and implement a national 
                                                                 
ePublic health surveillance is the ongoing, systematic collection, analysis, and interpretation of data for 
use in the planning, implementation, and evaluation of public health practice.  Desirable qualities of any 
system include simplicity, flexibility, acceptability, sensitivity, and representativeness.  A surveillance 
system also includes the timely dissemination of these data to persons who can undertake effective 
prevention and control activities, including clinicians, researchers, laboratorians,  and public health 
personnel.  (MMWR, Guidelines for Evaluating Surveillance Systems, May 6, 1988/37(S5); 118.) 
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AR surveillance plan:             
· Identify the components of a national AR surveillance plan and the roles of 
partners in its design and implementation. 
Coordinator: CDC; Collaborators: DoD, DVA, FDA, USDA, HCFA 
· Determine which surveillance activities should be conducted routinely at 
national, regional, state, or local levels and which may require specialized 
 projects.       
Coordinators: CDC, FDA, USDA 
· Define the roles of clinical, reference, public health, and veterinary laboratories 
at federal, state, and local levels in AR surveillance. 
Coordinator: CDC; Collaborators: DoD, DVA, FDA, USDA, HCFA 
· Improve coordination of AR surveillance systems at CDC, FDA, and USDA 
(e.g., identify components for integration). 
Coordinators: CDC, FDA, USDA 
· Consider the role of nongovernment funded surveillance and other data 
collection systems to augment a national surveillance plan. 
Coordinators: CDC, FDA, USDA 
· Ensure that the national AR surveillance plan is consistent with local and national 
surveillance methodology and infrastructure that currently exist or are being 
developed. 
Coordinators: CDC, USDA, FDA 
· Identify and assess practical surveillance strategies for components of the 
national plan by conducting pilot studies and demonstration projects.  
Coordinators: CDC, USDA, FDA       
Timeline for entire action item 2: Begin within one to two years 
 
(3) Develop standards and methodologies. 
· Develop standards and methodologies for monitoring drug-resistant microbes in 
humans, animals, and plants as well as for monitoring drug-resistant microbes in 
food products and environmental samples.    
Coordinators: CDC, UDSA, FDA, EPA 
· Develop standardized laboratory methodologies and data elements that allow 
susceptibility test results and AR surveillance data to be compared across 
geographic jurisdictions. 
Coordinators: CDC, USDA, FDA, EPA          
· Explore the use of standardized definitions and methodology (Related Action 
Item: Surveillance #5) to create an electronic surveillance system health care 
institutions can use to compare AR data from other local facilities. 
Coordinator: CDC; Collaborators: HCFA, DVA, DoD, HRSA 
· Encourage development of local, regional, and national data systems that allow 
linking of microbiology, clinical and pharmaceutical data that would support 
local decision making for prevention and control of antimicrobial resistance and 
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facilitate surveillance for antimicrobial resistance at all levels. 
Coordinator: CDC; Collaborators: HCFA, DVA, DoD, HRSA 
· Develop standards for reporting quantitative resistance data (e.g., minimal 
inhibitory concentrations or zone diameters) in ways that will detect decreased 
susceptibility.  These standards are necessary because numerical AR test results 
reported nonquantitatively (e.g., as susceptible, intermediate, or resistant) as 
“susceptible” may mask an emerging AR problem, i.e, microbes with a small 
decrease in susceptibility may still be classified as susceptible. 
Coordinators: CDC, USDA, FDA  
· Assess how current policies on maintaining the confidentiality of medical and 
veterinary data collected for other purposes relate to procedures for gathering 
data on antimicrobial resistance.  If necessary, develop a comprehensive 
national confidentiality policy on human and agricultural AR surveillance that 
includes both patient and institutional confidentiality, is consistent with 
confidentiality policies applied to other forms of surveillance and research data, 
and recognizes the differences in human and animal medicine and food 
production surveillance programs. 
Coordinator: CDC; Collaborators: DVA, HCFA, DoD, FDA, USDA 
Timeline for entire action item 3: Initiated 
 
(4) Address additional surveillance issues unique to AR. 
· Conduct post-marketing surveillance for the development of resistance to 
critical antimicrobial drugs.  Surveillance should be linked to information on drug 
use, and criteria should be developed to allow a prompt response to a finding of 
increased resistance associated with a specific pattern of use (e.g., consumer 
and professional alerts, enhanced education, labeling changes, or restrictions on 
use depending on the extent of and reasons for emergence of resistance). 
Coordinators: FDA, CDC, USDA 
· Facilitate the collection of AR surveillance data on pathogens for which cultures 
are not routinely obtained, either because the infections are empirically treated 
without laboratory diagnosis or because they are diagnosed with nonculture 
tests. 
Coordinator: CDC 
· Enhance availability of isolates of drug-resistant microbes to researchers (e.g., 
via a network of collections with an accessible databank).  
Coordinator: CDC; Collaborator: NIH 
Timeline for entire action item 4: Begin within one to two years 
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2. Goal: Collaborate with appropriate partners to develop procedures and methods for 
nationwide surveillance of antimicrobial drug use in human and nonhuman settings. 
    
a.  Action Items 
 
(5) TOP PRIORITY ACTION ITEM  - Develop and implement procedures for 
monitoring antimicrobial use in human medicine, agriculture, veterinary medicine, and 
consumer products: 
· Link human drug-use data to clinical information (e.g., diagnosis, severity of 
illness, and outcome). 
· Link agricultural drug-use data to species and usage patterns. 
· Assess potential effects of geographic variations in drug use on the incidence 
and prevalence of antimicrobial resistance. 
· Incorporate appropriate confidentiality protections. 
· Identify and anticipate gaps in availability of existing drugs.  (Related Action 
Item: Product Development  #79). 
Coordinators: CDC, FDA, USDA; Collaborators: EPA, DVA, DoD 
Timeline for entire action item 5: Begin within one to two years 
 
(6) Identify and evaluate methods for collecting (e.g., optimal sampling methods) and 
disseminating the surveillance data on antimicrobial drug use: 
· Identify inexpensive sources of drug use data (e.g., the National Ambulatory 
Medical Care Survey [NAMCS], the National Hospital Ambulatory Medical 
Care Survey [NHAMCS], and databases in some health care delivery systems 
and pharmacies) and evaluate their usefulness for surveillance purposes 
      Coordinators: CDC, FDA 
· Consider ways that results of periodic drug use surveys could be made available 
to food animal producers and veterinarians to encourage participation in data 
collection 
Coordinators: CDC, FDA, USDA 
Timeline for entire action item 6: Begin within one to two years 
 
(7) Work with accrediting agencies to address antimicrobial drug-use monitoring as part of 
quality assurance in health care delivery systems.  (Related Action Item: Prevention 
and Control #64) 
Coordinators: CDC, HCFA 
Timeline: Begin within one to two years 
 
B. Issue:  Implementation of the national plan for AR surveillance will require: 
· Reliable drug susceptibility data; 
· Adequate capacity and resources at state and local health and agricultural 
agencies; and 
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· An accessible, centralized source of AR data. 
 
1.  Goal: Promote the consistent and appropriate use of reliable laboratory tests for 
antimicrobial drug susceptibility. 
 
a. Action Items 
 
(8)  Ensure that clinical laboratories that provide data for AR surveillance purposes have 
access to and routinely participate in pertinent training and proficiency testing programs 
with good performance and indicate AR testing methodologies in their surveillance 
reports (e.g., specific automated methods or manual techniques). 
Coordinator: CDC; Collaborator: HCFA  
Timeline: Initiated 
 
(9) Evaluate the performance of licensed, automated AR testing devices in the  context of 
changing resistance patterns and update their labeling where appropriate (e.g., changes 
in quantitative resistance that may make a test result invalid). 
Coordinators: FDA, CDC  
Timeline: Initiated 
 
(10) Working with partners,b including the National Committee for Clinical Laboratory 
Standards (NCCLS), further develop, refine, and promote standardized clinical, 
epidemiologic, and laboratory methods for documenting and assessing the significance 
of drug resistance among yeasts and moulds, parasites, and viruses 
Coordinators: CDC, NIH, FDA, USDA, HCFA  
Timeline: Initiated 
 
(11) Identify ways to overcome economic, legal, and other barriers to appropriate AR 
testing and to the reporting of results (e.g., sufficient human resources, cost 
considerations, empiric treatment recommendations, managed-care practices, etc.). 
 (Related Action Item: Prevention and Control #34) 
Coordinators: HCFA, HRSA, CDC, AHRQ 
Timeline: Begin within one to two years 
 
(12) Pursue legal mechanisms for manufacturers to provide otherwise unavailable drugs 
to government reference laboratories for the sole purpose of antimicrobial drug 
susceptibility testing (as part of surveillance) with the understanding that these drugs 
will not be used for drug discovery purposes. 
Coordinator: CDC 
Timeline: Begin within one to two years 
 
2. Goal: Ensure that state and local health and agricultural agencies have the capacity to 
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conduct surveillance of drug-resistant organisms of public health importance. 
 
a. Action Items 
 
(13) With state health and agriculture departments and other stakeholders, define needed 
core capacity (the minimum needed in human, laboratory, and electronic resources) 
at the state and local level to ensure that basic AR surveillance is conducted in these 
jurisdictions.  As part of this effort, ensure that state public health and veterinary 
diagnostic laboratories maintain the capacity to test the drug-susceptibility patterns 
of resistant organisms of public health importance, especially for drug-
microorganism combinations for which testing methods are not routinely available at 
hospital and commercial laboratories. 
Coordinators: CDC, USDA, FDA 
Timeline: Begin within one to two years 
 
(14) Provide resources to assist in meeting state and local core capacity needs for AR 
surveillance.  Strive to provide consistent funding from year to year to state and 
local public health and veterinary diagnostic laboratories that meet quality assurance 
standards. 
Coordinators: CDC, USDA 
Timeline: Initiated 
 
3. Goal: Disseminate surveillance data in a timely manner to public health officials, clinicians, 
and others who may make decisions based on an analysis of the data. 
 
a. Action Items 
 
(15) Provide an accessible, centralized source of AR data from major surveillance 
systems involving animal and human populations.  In consultation with stakeholders, 
determine how to report AR data in a way that is valid and useful to interested 
parties (e.g., clinicians, public health officials, veterinarians, and researchers).  
Include sufficient detail in surveillance reports to permit local analysis and 
comparison with trends in drug use and medical and agricultural practices. 
Coordinators: CDC, USDA, FDA, HCFA 
Timeline: Begin within one to two years 
 
(16) Provide health care system administrators and other decision makers with data on 
the impact of drug-resistant organisms (e.g., outcome, treatment costs) and on 
effective prevention and control measures. 
Coordinators: CDC, AHRQ 
Timeline: Begin within one to two years 
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C. Issue: Monitoring AR in agricultural settings is essential to ensure animal and plant health and a 
safe food supply. 
 
1. Goal: Monitor AR in animal and plant pathogens and in bacteria that can be transmitted to 
humans through the food supply. 
 
a. Action Items 
 
(17) Expand and enhance coordination of surveillance for drug-resistance in enteric 
bacteria in sick and healthy humans and in sick and healthy animals on farms, at 
slaughter, and at retail.  This effort includes: 
· Expanding the National Antimicrobial Resistance Monitoring System:  Enteric 
Bacteria (NARMS:EB); 
· Comparing AR data on pathogenic and nonpathogenic organisms detected on 
farms (in sick and healthy animals), at slaughter, and in commercial food 
products; and 
· Utilizing these data to monitor the transmission of resistant infections and assess 
the effectiveness of prevention measures 
Coordinators: CDC, FDA, USDA  
Timeline: Initiated 
 
(18) Evaluate the usefulness of monitoring sentinel human populations (e.g., farm, 
abattoir, fruit and vegetable, and food processing plant workers) and persons in the 
general community for infection or colonization with resistant enteric bacteria. 
Coordinators: CDC, USDA, FDA 
Timeline: Begin within three to five years 
 
(19) Conduct pilot studies to assess the extent of environmental contamination by 
antimicrobial drug residues and drug-resistant organisms that enter the soil or water 
from human and animal waste.  If contamination is detected, conduct appropriate 
surveillance in waste, surface and ground water, and soil from agricultural areas in 
which waste is used for fertilizer, and conduct studies to determine potential impact 
on human and animal health.  (Related Action Item: Prevention and Control #55) 
Coordinators: EPA, CDC, USDA  
Timeline: Initiated 
 
(20) Gather information on the relationship between antimicrobial pesticide and herbicide 
use and the emergence of drug-resistance by monitoring: 
· The prevalence and incidence of drug-resistant organisms in agricultural areas 
where antimicrobial pesticides are used and areas where they are not used, and  
· The prevalence of colonization or infection with resistant bacteria in human or 
animal populations who live or work near orchards or who consume fruit 
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products sprayed (or treated) with antimicrobial. pesticides  (Related Action 
Item: Prevention and Control #62) 
Coordinators: EPA, CDC, USDA 
Timeline: Begin within three to five years 
 
II.  Prevention and Control 
 
Prevention and control of drug-resistant infections require measures to promote the appropriate use of 
antimicrobial drugs and prevent infection transmission.  The concept of appropriate use may be 
expressed in various other ways, e.g., good antimicrobial stewardship or judicious, prudent, or rational 
use.  In this Action Plan, appropriate antimicrobial drug use is defined as use that maximizes therapeutic 
impact while minimizing toxicity and the development of resistance. In practice, this means prescribing 
antimicrobial therapy when and only when beneficial to a patient; targeting therapy to the desired 
pathogens; and using the appropriate drug, dose, and duration. Appropriate antimicrobial drug use 
should not be interpreted simply as reduced use because these drugs offer valuable benefits when used 
appropriately. It is overuse and misuse that must be decreased to reduce the selective pressure favoring 
the spread of resistance.   
 
Appropriate use can be facilitated in various ways, e.g., by promoting informed prescribing by clinicians, 
informing consumers about the proper use and limitations of antimicrobial drugs, and improving 
diagnostic techniques.  The challenge facing public health organizations is to work with partners to 
identify effective methods of  promoting appropriate antimicrobial drug use and to translate these 
interventions into routine medical practice. 
 
Measures to prevent infection transmission, whether drug-resistant or not, are also very important in 
controlling AR.  These measures include the appropriate use of vaccines and infection control, 
sanitation, hygiene measures, and other safe behaviors, e.g., safe sexual practices.  Efforts to control 
drug-resistant infections must become part of everyday practice in health care settings across the nation, 
as well as in other settings (e.g., agriculture and veterinary medicine) in which antimicrobial drugs are 
used.  Partners in many sectors of society and the general public will need to be involved in this effort. 
 
A. Issue: Appropriate use of antimicrobial drugs can offer great benefits to patients, but overuse 
and misuse of these drugs can hasten the development of resistance and shorten the drug’s 
useful life. 
 
1. Goal: Identify effective methods for promoting appropriate antimicrobial use. 
 
a.  Action Items 
 
(21) Identify factors that promote or impede appropriate drug use in hospitals, extended 
care facilities, and outpatient settings in collaboration with partners.b 
Coordinator: CDC; Collaborators: FDA, AHRQ, DVA, DoD 
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Timeline: Initiated 
 
(22) Develop appropriate drug use policies and evaluate the impact (including on 
prescribing patterns, resistance rates, patient outcome, and cost) of implementing 
these policies in hospitals and other health care delivery settings.  Identify ways to 
increase adherence to appropriate use policies proven to be beneficial in 
collaboration with partners.b 
Coordinator: CDC; Collaborators: AHRQ, FDA, DVA, DoD, HCFA 
Timeline: Initiated 
 
(23) Evaluate the relationship between prescribing behavior and specific antimicrobial 
drug marketing and promotional practices.  Assess the public health effects of these 
practices in collaboration with partners.b 
Coordinators: CDC, FDA 
Timeline: Begin within three to five years 
 
(24) Help individual hospitals and health care systems analyze how the availability of AR 
data and computer-assisted decision support systems influences prescriber 
behavior, health outcomes, and costs.  This plan may include the provision of 
computer software and the establishment of projects that involve the Medicare Peer 
Review Organizations (PROs). 
Coordinator: CDC; Collaborators: HCFA, DVA, DoD 
Timeline: Begin within three to five years 
 
2. Goal:  Promote appropriate antimicrobial use through educational and behavioral 
interventions found to be effective. 
 
a. Action Items 
 
(25) TOP PRIORITY ACTION ITEM  - Conduct a public health education campaign 
to promote appropriate antimicrobial use as a national health priority.  The 
campaign should involve many partners.b   Elements of this campaign may include: 
· Culturally appropriate educational and behavioral interventions implemented 
through community-based programs that target patients and selected 
populations and communities, such as daycare centers and schools; 
· Strategies to improve patient adherence to appropriate therapies; 
· A clearinghouse for educational materials (e.g., booklets and CD-ROM 
presentations) on appropriate drug use and AR prevention; 
· A periodically updated priority list of drug-resistant microorganisms in humans 
and animals; and 
· A glossary disseminated through CDC Website that defines technical words 
commonly used in discussions of AR issues. 
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Coordinators: CDC, FDA; Collaborators: USDA, HCFA 
Timeline: Begin within one to two years 
 
(26) TOP PRIORITY ACTION ITEM  - In collaboration with many partners,b 
develop and facilitate the implementation of educational and behavioral interventions 
that will assist clinicians in appropriate antimicrobial prescribing.  Examples may 
include: 
· Educational curricula and training modules for all prescribing clinicians, health 
professions students, trainees, and senior health care administrators as part of 
quality assurance programs; 
· Clinical guidelines that address appropriate antimicrobial use; 
· Informatics technology (e.g., computer-assisted decision support) to assist in 
point-of-care prescribing and patient outcome monitoring; 
· Culturally appropriate materials and methods to help clinicians explain to 
patients the benefits and limitations of antimicrobial drugs and the importance of 
appropriate use of these drugs; and 
· Material that could be included in licensing, board certification, and credentialing 
examinations. 
Coordinators: CDC, FDA; Collaborators: DoD, DVA, HRSA, HCFA  
Timeline: Initiated   
 
3. Goal: Promote appropriate antimicrobial use through regulatory changes and public policy 
actions. 
 
a. Action Items 
 
(27) Explore ways to integrate appropriate use information into antimicrobial package 
inserts and promotional materials, to provide such information to patients with each 
prescription, and to provide clear guidance to industry to ensure that promotion of 
antimicrobials directed towards consumers encourages appropriate use and 
discourages inappropriate use.   
Coordinator: FDA; Collaborator: CDC  
Timeline: Initiated 
 
(28) Articulate factors that support the current approach of requiring prescription-only 
dispensing for all systemic (i.e., nontopical) antimicrobial drugs used in clinical 
medicine. 
Coordinator: FDA; Collaborator: CDC 
Timeline: Begin within one to two years 
 
(29) Periodically review and update antimicrobial drug susceptibility information included in 
drug labeling, with input from stakeholders and other experts, e.g., the National 
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Committee for Clinical Laboratory Standards (NCCLS) and CDC. 
Coordinator: FDA  
Timeline: Begin within one to two years 
 
(30) Convene an advisory panel or other expert group involving stakeholders and 
partnersb to consider issues related to resistant pathogens that cause serious 
infections for which available treatment options are very limited or nonexistent.  
Issues include: 
· Criteria for designating such drug-pathogen combinations; 
· Compiling and updating a list of such drug-pathogen combinations; 
· Recommendations for diagnosis and management of patients with suspected or 
documented infection, including where appropriate that selected important drugs 
be preferentially used for the treatment of conditions associated with organisms 
that are resistant to other drugs; 
· Publicizing and facilitating access to clinical trials or compassionate use of 
investigational therapies; 
· Recommendations for preventing infection transmission; 
· Recommendations for performance and reporting of susceptibility test results for 
selected important drugs by clinical laboratories including possibly that they be 
reported to clinicians only on request if an organism is sensitive to other 
appropriate drugs; 
· Monitoring the use of selected important drugs, with consideration of changes in 
product labeling by FDA and in recommendations for use if increased resistance 
is detected; and         
· Labeling by FDA of selected important drugs with the recommendation that 
they be preferentially used for the treatment of conditions associated with 
organisms that are resistant to other drugs. (Related Action Item: This item will 
also be considered in conjunction with Product Development #80.) 
Coordinators: FDA, CDC 
Timeline: Begin within one to two years 
 
(31) Convene a working group to examine the impact of federal reimbursement policies 
for home parenteral antimicrobial treatment, appropriate antimicrobial use, and 
appropriate use of antimicrobial susceptibility testing.  Where needed, the working 
group will make recommendations for modifying these policies. 
Coordinator: HCFA; Collaborators: CDC, HRSA 
Timeline: Begin within one to two years 
 
(32) Develop and submit measures for appropriate antimicrobial use to the National 
Committee for Quality Assurance for inclusion in Health Plan Employer Data and 
Information Set (HEDIS), which provides comparative data on managed care 
organizations. 
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Coordinator: CDC; Collaborator: HCFA 
Timeline: Initiated 
 
B. Issue: Improved diagnostic practices can enhance antimicrobial use and patient care. 
 
1. Goal: Identify and promote the widespread use of diagnostic testing and reporting 
strategies that effectively facilitate appropriate use of antimicrobial drugs in routine 
practice. 
 
a. Action Items 
 
(33)  Evaluate the potential impact of improved diagnostic tests, including rapid point-of-
care tests on antimicrobial drug use and patient care, and assess their financial 
implications.  Take into account tests that distinguish between bacterial and viral 
infections, tests that identify resistant pathogens, and tests that distinguish common 
clinical entities such as bacterial sinusitis and acute bacterial otitis media from 
illnesses with similar manifestations for which antimicrobials are not beneficial.  
(Related Action Item: Research #76) 
Coordinators: CDC, FDA, NIH; Collaborators: DVA, DoD,  
Timeline: Begin within one to two years 
 
(34) Identify economic and other barriers in the health care system (e.g., reimbursement 
policies by third-party payers, managed care practices, cost considerations, empiric 
treatment recommendations, etc.) to diagnostic testing that promotes appropriate 
use of antimicrobials.  Develop recommendations that remove disincentives or 
promote incentives to such testing. 
Coordinator: HCFA; Collaborators: CDC, HRSA; AHRQ 
Timeline: Begin within three to five years 
 
(35) In collaboration with professional societies, industry, health departments, and other 
stakeholders and partners,b develop guidelines for clinicians and clinical 
microbiology laboratories that address: 
· Appropriate specimen collection; 
· Performance, interpretation, and reporting of antimicrobial (including 
antibacterial, antifungal, antiviral, and antiparasitic) susceptibility tests performed 
on clinical specimens; and 
· Use of in-office (point-of-care) tests for infection, including AR infections. 
Coordinator: CDC; Collaborators: FDA, DoD, DVA, HCFA, HRSA 
Timeline: Begin within three to five years 
 
(36) In collaboration with professional societies, industry, health departments, and other 
stakeholders and partners,b develop guidelines that address the use of clinical 
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microbiology laboratories for use by health care delivery organizations.  The 
guidelines will: 
· Promote access to clinical microbiology services by clinicians; 
· Promote access to appropriate on-site microbiology services in acute care 
facilities; 
· Allow physicians to submit specimens to clinical laboratories other than those 
designated by their health care delivery organization or the patient’s insurance 
company, with appropriate justifications; and 
· Facilitate direct consultation between clinicians and laboratory personnel with 
appropriate expertise and authority. 
Coordinator: CDC; Collaborator: HCFA for bullet 2. 
Timeline: Begin within one to two years 
 
(37) Promote the increased performance of direct examination of microbiological 
specimens (e.g., by Gram stain or other rapid method), in circumstances where 
appropriate, clinically relevant, and reliable information can be garnered, as a readily 
available point-of-care diagnostic test.  This step will require working within the 
framework of the Clinical Laboratory Improvement Amendment (CLIA) regulations 
and involving medical education and health care delivery organizations. 
Coordinator: CDC; Collaborator: HCFA 
Timeline: Begin within one to two years 
 
C. Issue: Preventing infection transmission through improved infection control, behaviors that 
prevent infection (e.g., safe sexual practices),  and use of vaccines can help prevent the 
spread of antimicrobial resistance. 
 
1. Goal: Identify ways to reduce disease transmission in health care settings and in the 
community. 
 
a. Action Items 
 
(38) Identify factors that promote transmission of drug-resistant pathogens in health care 
facilities, in extended care facilities, and in community settings including daycare 
centers and in the community at large.  These may include characteristics of the 
facilities and of the populations that they serve. 
Coordinator: CDC; Collaborators: DVA, DoD 
Timeline: Initiated 
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(39) TOP PRIORITY ACTION ITEM   - Evaluate the effectiveness (including cost-
effectiveness) of current and novel infection-control practices for health care and 
extended care settings and in the community.  Promote adherence to practices 
proven to be effective. 
Coordinator: CDC; Collaborators: DoD, DVA, HCFA, HRSA 
Timeline: Initiated 
 
(40) Evaluate the cost-effectiveness and impact on patient care and drug resistance of 
medical devices that incorporate anti-infective compounds to prevent infection (e.g., 
anti-infective urinary catheters and prosthetic heart valves).  Where appropriate 
(e.g., shown to be effective and not induce resistance), encourage the clinical use of 
these devices.  (Related Action Item: Product Development #82) 
Coordinator: CDC; Collaborators: AHRQ, DoD, DVA, FDA, HRSA, 
HCFA 
Timeline: Begin within three to five years 
 
(41) Encourage the development and implementation of clinical alternatives to those 
invasive medical procedures and devices that increase the risk of infection in 
hospitals and other health care settings, e.g., substitution of transcutaneous 
monitoring of blood oxygen levels of indwelling catheters.   
Coordinator: CDC; Collaborators: FDA, DVA      
Timeline: Begin within  three to five years 
 
(42) Evaluate the benefits and risks of incorporating antimicrobial, disinfectant, or 
antiseptic chemicals into consumer products (e.g., soap, toys, kitchen utensils, 
clothes, paints, plastics, and film preservatives) and of applying disinfectants and 
sanitizers to hard, non-porous surfaces such as food-contact surfaces, hospital 
premises, bathrooms, etc.  Consider whether they have any efficacy in reducing 
infection and/or may play a role in promoting drug resistance. 
Coordinators: CDC, EPA; Collaborator: FDA 
Timeline; Initiated 
 
2. Goal: Promote infection control through behavioral and educational interventions. 
 
a. Action Items 
 
(43) Conduct a public health campaign to promote hand hygiene and other hygienic 
practices, as well as other behaviors that prevent the transmission of infectious 
organisms, in collaboration with professional societies and stakeholders.  This 
campaign may be coordinated with the public health education strategy to promote 
appropriate antimicrobial use described in Action Item #25:  Prevention and 
Control.  Components will include developing, evaluating, and facilitating the 
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implementation of school-based and other programs that promote hand hygiene and 
other behaviors that prevent infection, building on previous campaigns (e.g., 
American Society of Microbiology’s Operation Clean Hands).27 
Coordinator: CDC  
Timeline: Begin within one to two years 
 
(44) Facilitate and support the activities of infection control programs in health care 
settings as a component of medical care.  Promote infection control education at all 
stages of training and practice for all health care workers who have contact with 
patients. 
Coordinator: CDC; Collaborators: DVA, HCFA, DoD, HRSA 
Timeline: Initiated 
 
(45) Support ongoing public health education campaigns on food safety, such as FDA 
and USDA’s Fight Bac program,28 whose aims are to educate food producers, 
suppliers, retailers, and consumers about food safety practices that reduce 
foodborne infections (including AR infections).29 
Coordinators: USDA, CDC, FDA 
Timeline: Initiated 
 
(46) Educate the public about the merits and safety of irradiation as one tool to reduce 
bacterial contamination of food. 
Coordinator: CDC 
Timeline: Begin within one to two years 
 
3. Goal: Optimize the use of vaccines to prevent drug-resistant infections and reduce 
antibiotic use. 
 
a. Action Items 
 
(47) Support community-based programs that promote and facilitate availability of 
recommended vaccinations for adults and children. 
Coordinator: CDC 
Timeline: Initiated 
 
(48) Identify vaccines useful in preventing drug-resistant infections and reducing 
antimicrobial drug use, and evaluate novel methods for improving coverage with 
these vaccines.  For example:  
· Evaluate the risks and benefits of allowing certain vaccines for adults (e.g., for 
pneumococci and influenza virus) to be dispensed by pharmacists without 
prescription and 
· Review and evaluate methods to promote administration of pneumococcal 
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vaccines (e.g., offering vaccination when patients are discharged from the 
hospital), and encourage the use of methods found to be effective. 
Coordinator: CDC; Collaborators: DVA, FDA, HCFA 
Timeline: Begin within three to five years 
 
D. Issue: Prevention and control of drug resistance in agriculture and veterinary medicine is 
important to promoting animal and plant health, as well as in preventing AR transmission 
to humans through the food supply or through contact with infected animals or the 
environment. 
 
1. Goal: Improve understanding of the risks and benefits of antimicrobial use, and ways to 
prevent the emergence and spread of drug resistance, in agricultural and veterinary 
settings. 
 
 a. Action Items 
 
(49) Evaluate the nature and magnitude of the impact of using various antimicrobial drugs 
as growth promotants in different species, using current animal husbandry practices. 
 Use this information to assist in risk-benefit assessments of such use. 
Coordinator: USDA; Collaborators: CDC, FDA 
Timeline: Begin within one to two years 
 
(50) Conduct additional research to further define the effects of using various veterinary 
drugs on the emergence of resistant bacteria that infect or colonize food animals of 
different species, using various animal husbandry practices.  Identify risk factors and 
preventive measures.  Assess the associated risk of:  
· Transmission of AR infections to humans; 
· Clinical disease in humans; and 
· Transfer of resistance factors from animal flora to human flora. 
Coordinators: CDC, USDA, FDA 
Timeline: Initiated 
 
(51) Conduct epidemiologic and laboratory studies to assess the risk of development 
and transfer of resistance related to the use of antimicrobial drugs in food and 
nonfood plants, and identify risk factors and potential preventive measures. 
Coordinator: USDA; Collaborators: CDC, FDA, EPA 
Timeline: Initiated 
 
(52) Develop rapid tests for inspecting fresh commodities like fruit for evidence of 
contamination with bacteria that are resistant to antibiotics. 
Coordinator: USDA; Collaborators: EPA, FDA, CDC 
Timeline: Begin within one to two years 
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(53) Evaluate the effect of current food processing and distribution methods on the 
emergence and spread of drug-resistant organisms. 
Coordinator: USDA; Collaborators: CDC, FDA 
Timeline: Begin within one to two years 
 
(54) Identify and evaluate new food pasteurization strategies. 
Coordinator: USDA; Collaborators: FDA, CDC  
Timeline: Begin within three to five years 
 
(55) Assess the risk of AR emergence and spread due to environmental contamination 
by antimicrobial drugs or by resistant bacteria in animal and human waste.  Collect 
information on whether environmental contamination by antimicrobial drugs can lead 
to the development of resistance in bacteria that live in the soil or in water.  (Related 
Action Item:  Surveillance #19) 
Coordinators: USDA, CDC, EPA, FDA      
Timeline: Initiated 
 
(56) Assess the impact of antimicrobial use in companion animals (pets) on colonization 
and infection with drug-resistant organisms in the animals and their human household 
contacts. 
Coordinator: CDC 
Timeline: Begin within three to five years 
 
2. Goal: Promote appropriate antimicrobial use in agricultural and veterinary settings. 
 
a. Action Items 
 
(57) Work with veterinary and agricultural communities to help educate users of 
veterinary and agricultural antimicrobials about AR issues, and promote the 
implementation and evaluation of guidelines that address these issues: 
· Appropriate antimicrobial use in agricultural and veterinary settings; 
· Performance and interpretation of antimicrobial susceptibility tests performed on 
specimens from different species of animals; and 
· Point-of-care tests for infection, including AR infections. 
Coordinators: USDA, CDC, FDA; Collaborator: EPA 
Timeline: Initiated 
 
(58) TOP PRIORITY ACTION ITEM  - In consultation with stakeholders, refine and 
implement the proposed FDA framework30 for approving new antimicrobial drugs 
for use in food-animal production and, when appropriate, for re-evaluating currently 
approved veterinary antimicrobial drugs.  The proposed framework includes the 
following major steps: 
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· Categorize antimicrobial drugs according to their importance in human medicine. 
Timeline: Initiated 
· Develop an approach to the establishment of thresholds for drug resistance in 
selected pathogens. 
Timeline: Initiated 
· Revise requirements for the industry’s submission of drug use data. 
Timeline: Initiated 
· Develop procedures to assess microbial safety of antimicrobial drug use in 
food-producing animals. 
Timeline: Initiated 
In support of the concepts articulated in the framework document: 
· Conduct risk assessments on the human health impact of using selected 
antimicrobials important in human medicine in food-producing animals 
Timeline: Initiated 
· Initiate appropriate steps to address any unacceptable human health impact, if 
identified by the risk assessments, for drugs categorized as being of critical 
importance in human medicine 
Timeline: Begin within one to two years 
Coordinator: FDA 
 
(59) Strongly encourage involvement of veterinarians in decisions regarding the use of 
systemic antimicrobial drugs in animals, regardless of the distribution system through 
which the drug is obtained (e.g., regardless of whether a prescription is required to 
obtain the drug). 
Coordinators: FDA, USDA 
Timeline: Initiated 
 
(60) Evaluate the potential impact of making all systemic veterinary antimicrobial drugs 
available by prescription only. 
Coordinators: FDA, USDA 
Timeline: Begin within three to five years 
 
(61) Convene an expert group to consider how to incorporate AR issues into regulations 
governing the registration and use of antimicrobials and antibiotic pesticides.  Invite 
external experts, stakeholders, and the public to provide input. 
Coordinator: EPA 
Timeline: Begin within one or two years 
 
  
 
 31
E. Issue: Efforts to prevent and control AR emergence and spread must be comprehensive and 
multifaceted, involve a wide variety of nonfederal partners and the public, and become a 
part of routine practice nationwide. 
 
1. Goal: Ensure input from nonfederal experts on federal efforts to combat antimicrobial 
resistance. 
 
a. Action Item   
 
(62) Establish an ongoing mechanism to obtain periodic input from external experts on 
AR issues.  This process will include ensuring input from stakeholders and partnersb 
(e.g., state and local health agencies, the private sector, and the public) in 
developing and reviewing federal efforts to address antimicrobial resistance. 
Coordinators: CDC, FDA, NIH; Collaborators: USDA, EPA, DoD, DVA, 
AHRQ, HRSA, HCFA 
Timeline: Begin within one to two years 
 
2. Goal: Develop and evaluate comprehensive demonstration programs to prevent and 
control AR. 
 
a. Action Item 
 
(63) TOP PRIORITY ACTION ITEM - Support demonstration projects to evaluate 
comprehensive strategies that use multiple interventions to promote appropriate 
drug use and reduce infection rates.  These projects will include the following steps: 
· Assess how interventions found effective in research studies can be applied 
routinely and most cost-effectively on a large scale; 
· Evaluate the use of these programs in health care systems (federal and 
nonfederal), in the community, and in agricultural and veterinary settings; and 
· Involve partnerships with local and state agencies, health care systems, 
professional societies, community organizations, schools, private industry, and 
the public. 
Coordinator: CDC; Collaborators: FDA, DVA, DoD, HRSA, HCFA,     
Timeline: Initiated 
 
3. Goal: Incorporate into routine clinical practice AR prevention strategies and programs that 
have been found to be beneficial in research and demonstration projects. 
 
a. Action Items    
 
(64) Utilize federal health care systems (e.g., DoD, DVA) as models for AR surveillance 
and prevention and control activities involving appropriate drug use, optimized 
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diagnostic testing, infection control, and vaccination practice. 
Coordinators: CDC, DVA, DoD, HCFA, HRSA 
Timeline: Begin within three to five years 
 
(65) For all health care systems for which federal funds are provided, identify and 
promote strategies to establish AR prevention and control activities as part of 
quality monitoring programs. 
Coordinators: CDC, DVA, DoD, HCFA, HRSA 
Timeline: Initiated 
 
(66) Encourage nationally recognized accrediting agencies such as the National 
Committee for Quality Assurance (NCQA) and the Joint Commission on 
Accreditation of Healthcare Organizations (JCAHO) to include accreditation 
standards that promote efforts to prevent and control AR, including appropriate 
antimicrobial use, infection control, vaccine use, and diagnostic testing.  These 
standards may draw on the findings of existing data and demonstration programs 
and AHRQ Evidence-Based Practice Centers. 
Coordinator: CDC; Collaborators: HCFA, AHRQ 
Timeline: Begin within one to two years 
 
III. Research 
 
Antimicrobial resistance is among the most challenging problems in microbiology, clinical medicine, and 
public health.  Antimicrobial resistance is not one problem, but an overarching term for an array of 
problems inherent in the evolution of microbes and influenced by antimicrobial use. Basic and clinical 
research provides the fundamental knowledge necessary to develop appropriate responses to 
antimicrobial resistance emerging and spreading in hospitals, communities, farms, and the food supply.  
Major scientific accomplishments throughout the years have contributed much to the understanding of 
the fundamental biological processes of AR within microbes and the resulting impact on humans, 
animals, and the environment.  This knowledge base provides us the opportunity to influence these 
processes and outcomes. 
 
Because of its broad scope, the U.S. research community has a major contribution to make in meeting 
the goals the AR Task Force has set forth.  The research and development of diagnostic tests, new 
antimicrobial agents, novel therapeutic products, and vaccines and other preventive approaches in 
response to AR is a multistep process that begins with basic research discoveries and ends with the 
availability and use of a new product or implementation of a process.  Along this pathway three areas 
need to be addressed: the identification of gaps and needs in the molecular and cellular understanding of 
resistance, the infrastructure to support a robust research community, and a means for moving research 
findings into the development of new products. 
 
The Interagency Task Force has worked with representatives from the public and private sector to 
  
 
 33
identify important research needs in microbial physiology, ecology, genetics and mechanisms of 
resistance.  Existing gaps in knowledge and understanding should be addressed to augment the federal 
and private sector response to the overall problem.  Efforts are underway to build and enhance the field 
of AR research, through increased focus, recognition, and collaboration.  The aim is to develop a 
research infrastructure to support a critical mass of AR researchers who will interact, exchange 
information, and stimulate new discoveries.  In order to move novel ideas arising in the research 
laboratory to useful products or approaches, support of the underlying infrastructure to study and test 
products and a mechanism to transition to industrial partners is necessary. 
 
This effort will involve federal agencies that conduct, support and promote basic and clinical research in 
academia and industry and will involve prioritizing needs, identifying key opportunities, recruiting new 
investigators to the field, and making responsible use of resources to address AR problems. 
 
A. Issue:  Specific scientific gaps remain in the understanding of microbial physiology, ecology, 
genetics and mechanisms of resistance. 
 
1.Goal: Identify gaps and address existing research needs and identify new ones. 
 
a.  Action Items 
 
(67) Additional research, including high risk and high payoff research in nontraditional 
fields, is needed to enhance the understanding and assess the impact of: 
· Mechanisms of AR emergence, acquisition, spread, persistence, and decline, 
with special regard to multidrug resistant organisms; 
· Emergence and transfer of resistance genes among microorganisms in vivo, 
including epidemiologic factors; 
· Microbial ecology and the role of normal flora as a repository of resistance 
factors, as well as the use of susceptible bacterial populations in the control of 
antimicrobial resistance; 
· Effects of preventive, therapeutic, growth-promoting agents and residues of 
agents in the environment on the microbiota of animals, plants, soil, and aquatic 
environments; 
· Host factors and immune modulators (e.g., cytokines) in clinical resistance to 
treatments for opportunistic infections; 
· The determinants of colonization and infection with drug-resistant pathogens; 
and 
· Variations in antimicrobial use patterns that may affect the emergence and 
spread of resistance and the outcome of treatment, such as: 
o Differences in duration and dosage in the administration of antimicrobial 
agents; 
o Prophylactic use of antimicrobial (including antibacterial and antifungal) 
agents; 
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o Drug combinations used to treat resistant organisms; and 
o The rotation (cycling) of antimicrobial drugs and other similar changes in 
selection and use of drug classes. 
Coordinator: NIH; Collaborators: CDC, FDA, DVA, USDA, EPA, DoD 
Timeline: Initiated 
 
(68) Conduct further government-wide assessments with external input on the scope and 
composition of AR research to identify research opportunities. 
Coordinators: NIH, CDC, FDA, USDA; Collaborators:  DoD, DVA, 
AHRQ, EPA, HCFA 
Timeline: Initiated 
 
B. Issue: The existing research infrastructure needs to ensure a critical mass of researchers in AR 
and related fields. 
 
1. Goal: Augment the scientific research infrastructure. 
 
a.  Action Items 
 
(69) Work with the appropriate peer review structures to ensure that the requisite 
expertise is applied to the review process to facilitate funding of quality AR 
research. 
Coordinators: NIH, DVA, FDA 
Timeline: Begin in one to two years 
 
(70) TOP PRIORITY ACTION ITEM  - Provide to the research community 
genomics and other powerful technologies to identify targets in critical areas for the 
development of new rapid diagnostics methodologies, novel therapeutics, and 
interventions to prevent the emergence and spread of resistant pathogens.  
Examples include tools such as microbial genome sequences, information on 
comparative genomics, DNA chip technology, informatics, and assistance in the 
application and use of these tools. 
Coordinator: NIH; Collaborators: DoD, USDA, FDA 
Timeline: Initiated 
 
(71) Encourage sharing of AR data between industry and the research community, 
including genomics and other technologies. 
Coordinator: NIH; Collaborators: DoD, USDA, FDA 
Timeline: Begin in three to five years 
 
2. Goal: Develop a critical mass of researchers in AR. 
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a. Action Items 
 
(72) Bring new researchers into the field, by utilizing appropriate strategies such as 
training and research opportunities. 
Coordinator: NIH; Collaborators: CDC, FDA, USDA, DoD, DVA 
Timeline: Initiated 
 
(73) Organize conferences that address research issues relating to AR. 
Coordinator: NIH; Collaborators: CDC, USDA, FDA, DVA, DoD, AHRQ 
Timeline: Initiated 
 
C. Issue: Special efforts are needed to translate research findings into medically useful products 
for human and agricultural/veterinary use, such as novel antimicrobial therapeutics, 
diagnostic tests, vaccines and other tools for preventing AR emergence and spread. 
 
1. Goal: Address the governmental role in translating novel ideas into new clinically relevant 
products, focusing on gaps not filled by pharmaceutical industry and other 
nongovernment groups. 
 
a. Action Items 
 
(74) Explore the need to encourage preclinical studies on the toxicology, 
pharmacokinetics, and pharmacodynamics of novel therapeutic agents for the 
treatment of multidrug-resistant pathogens and facilitate the transition of potential 
products from preclinical to clinical studies leading to development by industry of 
novel therapeutic agents. 
Coordinator: NIH; Collaborators: DoD, DVA, FDA, USDA 
Timeline: Begin within one to two years 
 
(75) TOP PRIORITY ACTION ITEM  - In consultation with academia and the 
private sector, identify and conduct human clinical studies addressing AR issues of 
public health significance that are unlikely to be studied in the private sector, such as: 
· Novel therapies; 
· Existing antimicrobials administered in treatment regimens and combinations that 
may not be included in approved indications and dosing schedules; and 
· Other products and practices relevant to the control and treatment of 
antimicrobial-resistant pathogens including devices, diagnostics, antimicrobial 
soaps, disinfectants, etc. 
Coordinator: NIH; Collaborators: CDC, DVA, DoD, FDA 
Timeline: Begin within one to two years 
 
2. Goal: Develop rapid, inexpensive, point-of-care diagnostic methods to facilitate 
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appropriate use of antimicrobials. 
 
a. Action Item 
 
(76) TOP PRIORITY ACTION ITEM  - Identify, develop, test, and evaluate new 
rapid diagnostic methods for human and veterinary uses with partners including 
academia and the private sector.  Such methods should be accurate, affordable, and 
easily implemented in routine clinical settings and may include: 
· Tests for resistance genes that are associated with drug resistance, including 
nonculture specimens; 
· Rapid point-of-care diagnostics for patients with viral respiratory infections and 
clinical syndromes such as otitis media, sinusitis, and pneumonia; and 
· Rapid methods for detecting drug resistance among fungi, parasites, viruses, and 
mycobacteria. 
Coordinators: NIH, FDA; Collaborators: DoD, USDA, CDC, AHRQ, DVA 
Timeline: Initiated 
 
3. Goal: Develop new products and strategies to prevent and treat colonization and infection 
with resistant organisms in patients, prevent transmission of resistant infections in the 
community, and prevent AR emergence 
 
a. Action Items 
 
(77) TOP PRIORITY ACTION ITEM  - Encourage basic and clinical research in 
support of the development and appropriate use of vaccines in human and 
veterinary medicine in partnership with academia and the private sector.  Vaccines 
are needed to: 
· Prevent viral infections that predispose patients to and are difficult to 
differentiate from bacterial infection and are  presumptively treated with 
antibacterial agents (e.g., influenza virus); 
· Prevent colonization, infection, and transmission of resistant organisms such as 
enterococci and staphylococci; and 
· Prevent common bacterial infections (such as S. pneumoniae, nontypable 
Haemophilus influenzae) to reduce antibacterial use. 
Coordinators: NIH, FDA; Collaborators: CDC, DoD, DVA, USDA  
Timeline: Initiated 
 
(78) Encourage basic and clinical research in support of novel approaches to preventing 
or treating infections with resistant organisms that occur in humans and animals by 
partnering with academia and the private sector.   Novel approaches may include: 
· Bacteriophage therapy; 
· Active (vaccine) and passive (antibody, hyperimmune globulin) immunization; 
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· Host-derived antimicrobial agents; 
· Nonantibiotic antimicrobials and nonchemical approaches with broad or 
nonspecific anti-infective activities (e.g., defending and nonspecific 
immunostimulants, such as defensins, ribozymes, etc.); and 
· Microbial ecology (probiotics, direct fed microbials, etc.). 
Coordinator: NIH; Collaborators: DoD, DVA, FDA, USDA, CDC 
Timeline: Initiated 
 
IV. Product Development 
 
New products are not being developed rapidly enough to address increasing microbial resistance.  
Needed products include not only new classes of antimicrobials able to kill otherwise resistant 
organisms, but also vaccines and anti-infective devices with the potential to prevent infections as well as 
improved diagnostic tools to aid in appropriate use of therapeutics.  With respect to antimicrobial drugs, 
each new agent represents a major investment by a pharmaceutical company, which must shepherd the 
product through pre-clinical studies and clinical testing, followed by large and expensive clinical trials.  
Pharmaceutical companies may be reluctant to invest extensive resources in the development of drugs, 
such as those antimicrobials targeted to resistant organisms, which are often given for short time periods 
to small numbers of patients.  Manufacturers are similarly concerned that appropriate use policies may 
limit sales and profits.  On the other hand, when a drug is used widely, allowing recovery of costs and 
profitability, resistance may develop more rapidly and shorten the useful life of the drug. 
 
Due to these economic realities – as well as to scientific limitations and a lag in the perception of a need 
for new agents – very few novel antimicrobial drugs have reached the market for several years.  A 
major aim of this interagency effort is to work with the private sector to explore and test innovative 
ways to address these issues.  Approaches to be considered include providing incentives (and 
overcoming disincentives) to promote and assist the development of important products to address AR. 
 
Product development is also a very important issue for veterinary medicine and agriculture.  U.S. 
agencies and private sector partners must intensify efforts to encourage the development and use of 
veterinary drugs and agricultural practices that are unlikely to stimulate resistance to important human 
drugs or spread resistant pathogens to humans.  Again, increased attention also needs to be turned to 
strategies to prevent infections of animals (e.g., vaccines, changes in husbandry) and to the improved 
use of existing and new products. 
 
A. Issue: Researchers and drug manufacturers need to be better informed of current and 
projected gaps in the arsenal of antimicrobial drugs, vaccines, and diagnostics and of 
potential markets for these products. 
 
1. Goal: Provide a systematic assessment of the current status and projected future needs for 
AR products. 
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a.  Action Item 
 
(79) TOP PRIORITY ACTION ITEM  - Create an Interagency AR Product 
Development Working Group to identify and publicize priority public health needs in 
human and animal medicine for new AR products (e.g., innovative drugs, targeted 
spectrum antibiotics, point-of-care diagnostics, vaccines and other biologics, anti-
infective medical devices, and disinfectants).  The Working Group will take these 
steps: 
· Obtain input from stakeholders, including pharmaceutical companies, 
physicians, epidemiologists, and microbiologists, on which products are needed; 
· Involve experts in the nonmedical disciplines (e.g., engineering and remote 
sensing, etc.); 
· Model future resistance trends, product needs, and potential markets 
(particularly for novel and narrow spectrum uses), taking into account AR 
surveillance data and numbers of patients at high risk of developing drug 
resistant infections (e.g., increases in immunocompromised patients); 
· Evaluate current market incentives for the development of priority AR products 
(Related Action Item: Product Development #80); 
· Reassess AR product priorities on a regular basis;  
· Evaluate the availability of currently approved, critical products where shortages 
or potential for shortages exists and develop an approach to ensure that the 
supply of such products is adequate to meet public health needs; and 
· Communicate the information and priorities developed by the Workgroup to 
inform and allow coordination with planning and action efforts in research, 
prevention and control, and product development. 
Coordinators: FDA, USDA, CDC; Collaborators: NIH, AHRQ 
Timeline: Begin within one to two years 
 
B. Issue: Existing market incentives and regulatory processes may be insufficient to stimulate the 
development of certain priority AR products while fostering their appropriate use. 
 
1. Goal: Investigate and act upon potential approaches for stimulating and speeding the entire 
AR product development process, from drug discovery through licensing. 
 
a. Action Items 
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(80) TOP PRIORITY ACTION ITEM  - Identify ways (e.g. financial and/or other 
incentives or investments) to promote the development and/or appropriate use of 
priority AR products, such as novel compounds and approaches, for human and 
veterinary medicine for which market incentives are inadequate. 
· This process should include consultation with outside stakeholders, economic 
consultants, and the AR Product Development Working Group (Related Action 
Item: Product Development  #79). 
· All such proposals will require careful economic modeling and analysis.  New 
approaches should be used on a trial basis for appropriate time periods and the 
costs and benefits of incentives used in these pilot programs should be 
monitored to assess the return on the public investment. 
· Similar incentives should be explored for ensuring adequate availability of 
existing products that meet critical public health needs but for which market 
incentives are inadequate to assure supply. (Related Action Item: Product 
Development #79). 
Coordinators: FDA, CDC; Collaborators: USDA, AHRQ 
Timeline: Begin within one to two years 
 
(81) Consider, in consultation with academia and industry, whether government has a 
constructive role to play in discovery of drugs and other products targeted to 
address areas where market incentives are limited and unmet needs exist (e.g., 
novel antimicrobial drugs targeted to specific resistant organisms).  (Related Action 
Items: Research Issue B) 
· Such a role could utilize intramural, extramural or partnership type mechanisms. 
 Products developed under such mechanisms could be licensed commercially 
either with or without specific stipulations regarding use.  
Coordinator: NIH; Collaborators: USDA, FDA, CDC 
Timeline: Begin within three to five years 
 
(82) Continue ongoing approaches that streamline the regulatory process, including 
clinical trials and enhanced pre-clinical studies (e.g., use of pharmacokinetics, and 
pharmacodynamics data) to help bring AR products (including drugs, vaccines, 
diagnostics and devices) to market as efficiently and rapidly as possible, while still 
assuring their safety and efficacy. 
· This approach might involve use of an expedited process in which certain drugs 
are considered for approval, in accordance with Subpart E of the Investigational 
New Drug (IND) regulations.  It might also involve defining new surrogate 
endpoints that indicate a meaningful response benefit over existing treatments for 
particular infections (e.g., HIV-1 RNA viral loads or CD4 counts as surrogate 
markers in the treatment of HIV/AIDS), in accordance with Subpart H of New 
Drug Application (NDA) regulations. 
· In the case of approvals for anti-infective medical devices, AR concerns will be 
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addressed during the pre-and post-licensing review, to ensure that these 
products reduce infection without engendering significant resistance. 
· For products specifically targeted to serious or life-threatening AR infections, 
for which there are few therapeutic alternatives, develop approaches for more 
focused development programs that would streamline product availability.  This 
should be done in consultation with all of the stakeholders in the process.  
Coordinator: FDA; Collaborator: USDA 
Timeline: Initiated 
 
C. Issue: The development and use of antimicrobial drugs and related products in agriculture and 
veterinary medicine should be optimized to reduce the development and transfer of 
resistance to pathogens that can infect humans. 
 
1. Goal: Promote the development and use of new and existing AR products that reduce the 
risk of the development and transfer of antimicrobial resistance to humans, as well 
as new approaches to reducing agricultural and veterinary use of antimicrobial 
drugs. 
 
a. Action Items 
 
(83) In consultation with stakeholders and expert consultants, identify ways to promote 
the development of new and alternative veterinary treatments and the improved use 
of existing therapies that are unlikely to stimulate resistance to drugs in human 
medicine.  This action will include consideration of the incentives and approaches 
listed in Action Items #80 (Product Development), #28 (Prevention and Control), 
and #78 (Research) and the implementation of pilot programs to stimulate the 
development of priority products that meet critical animal health needs.  
· Approaches for evaluation should include ways to improve and/or reduce the 
use of specific antimicrobial drugs, as well as ways to prevent infection, such as 
vaccines, changes in animal husbandry, and the use of competitive exclusion 
products (e.g., treatments that affect the intestinal flora of food animals). 
Coordinators: FDA, USDA, NIH, CDC 
Timeline: Begin within three to five years 
 
(84) Streamline the regulatory and approval process for veterinary antimicrobial drugs 
and related products that are unlikely, now or in the future, to result in transfer of 
antimicrobial resistance to humans. 
Coordinators: FDA, USDA      
Timeline: Begin within three to five years 
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